[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639308":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":60,"collaborators":26,"id":63,"slug":26,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"repeated transcranial magnetic stimulation group","ACTIVE_COMPARATOR","The rTMS group was given 1 Hz\u002Fs for 20 minutes for 3 weeks.",[13],"Device: rTMS group",{"label":15,"type":16,"description":17,"interventionNames":18},"sham repetitive transcranial magnetic stimulation group","SHAM_COMPARATOR","For the sham rTMS group, the coil was placed over the mPFC with the rTMS function disabled, and pre-recorded acoustic artifacts were played to mimic the auditory experience of the rTMS group.",[19],"Device: sham device",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","rTMS group","Patients with IBS-D received repetitive transcranial magnetic stimulation at 1 Hz\u002Fs for 20 minutes for 3 weeks.",[9],null,{"type":22,"name":28,"description":17,"armGroupLabels":29,"otherNames":30},"sham device",[15],[31],"sham transcranial magnetic stimulation",[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Xiuji Kan","CONTACT","15339525666","xiujikan@163.com",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Suzhou","Jiangsu","215006","China",{"type":46,"coordinates":47},"Point",[48,49],120.59538,31.30408,{"lat":49,"lon":48},[52,56,58],{"name":53,"role":35,"phone":54,"phoneExt":26,"email":55},"Wu Shuangjie","+8651267972743","sdfyec@163.com",{"name":34,"role":57,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"name":59,"role":57,"phone":26,"phoneExt":26,"email":26},"Ruixia Weng, Dr",{"type":57,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Rui Li","Chief of the Department of Gastroenterology","100639308",false,"NCT07581756","Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","Repeated Transcranial Magnetic Stimulation (rTMS) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","rTMS","Inclusion Criteria:\n\nEligible participants had to be between 18- 60 years of age and fulfill the Rome IV criteria for IBS-D. Specifically, patients must have experienced recurrent abdominal pain at least one day per week in the last three months, with symptom onset at least six months prior to diagnosis, associated with defecation or a change in the frequency or form (appearance) of stool. More than 25% of stool episodes be classified as Bristol Stool Form Scale (BSFS) type 6 or 7, and fewer than 25% as type 1 or 2. In addition, patients were required to exhibit moderate to severe symptoms, defined as an Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) score greater than 175 (on a 500-point scale). Dietary preferences of all participants included non vegetarian options and participants maintain stable dietary habits for at least one month prior to randomization. Moreover, patients aged over 50 were required to provide documentation of a normal colonoscopy performed within the preceding three years.\n\nExclusion Criteria:\n\nThe exclusion criteria included a completion rate of daily diaries of less than 50% during the screening period, a history of organic gastrointestinal disease, such as inflammatory bowel disease, a history of surgical resection of the GI tract or cholecystectomy, a recent diagnosis of Helicobacter pylori infection within the past 2 years, a history of gluten or lactose intolerance, a history of malignancy, or a history of neurological or psychiatric conditions. Additionally, individuals with severe systemic diseases, including uncontrolled diabetes mellitus, hyperthyroidism, or severe hepatic, renal, or cardiac insufficiency, were excluded. The use of probiotic or prebiotic supplements, antibiotics (including rifaximin), prokinetic or antidiarrheal agents, tricyclic antidepressants, or immunosuppressive therapies was not permitted within 4 wk prior to screening. Prohibited conditions during the study period included pregnancy, lactation, or being within 12 months postpartum. Lastly, participants with severe needle phobia, metal allergies, implanted cardiac pacemakers, or a known allergic diathesis were excluded. All participants provided their voluntary, written, informed consent prior to their inclusion.","ALL","18 Years","70 Years",{"count":74,"type":75},46,"ESTIMATED","INTERVENTIONAL",[78],"NA","Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential underlying mechanisms by which rTMS alleviates clinical symptoms in IBS-D patients.\n\nDesign: This is a clinical trial that uses clinical symptom scales to assess the therapeutic effect of rTMS on IBS-D patients. Meanwhile, gut microbiota and metabolite profiling, as well as the methane-hydrogen breath test, will be applied to investigate the mechanism of action from the perspectives of gut microecology, intestinal motility, and metabolism, so as to provide scientific evidence for the clinical application of rTMS in the treatment of IBS-D.",[81,82,83,84,85],"Irritable Bowel Syndrome","Irritable Bowel Syndrome With Diarrhea (IBS-D)","Repetitive Transcranial Magnetic Stimulation (rTMS)","Chronic Diarrhea","Intestinal Flora",[87,83],"Irritable Bowel Syndrome with diarrhea (IBS-D)","2026-05-06",{"date":90,"type":91},"2026-05-12","ACTUAL",{"date":93,"type":91},"2024-12-01",{"date":95,"type":75},"2026-07-01",{"name":5,"class":6},1]